425 related articles for article (PubMed ID: 28989103)
1. Antimalarial drug toxicities in patients with cutaneous lupus and dermatomyositis: A retrospective cohort study.
Mittal L; Zhang L; Feng R; Werth VP
J Am Acad Dermatol; 2018 Jan; 78(1):100-106.e1. PubMed ID: 28989103
[TBL] [Abstract][Full Text] [Related]
2. Adverse cutaneous reactions to hydroxychloroquine are more common in patients with dermatomyositis than in patients with cutaneous lupus erythematosus.
Pelle MT; Callen JP
Arch Dermatol; 2002 Sep; 138(9):1231-3; discussion 1233. PubMed ID: 12224986
[TBL] [Abstract][Full Text] [Related]
3. Adverse cutaneous drug reactions with antimalarials in cutaneous lupus and dermatomyositis: A retrospective cohort study.
Gonzalez CD; Hansen C; Clarke JT
J Am Acad Dermatol; 2019 Sep; 81(3):859-860. PubMed ID: 31085265
[No Abstract] [Full Text] [Related]
4. The effect of increasing the dose of hydroxychloroquine (HCQ) in patients with refractory cutaneous lupus erythematosus (CLE): An open-label prospective pilot study.
Chasset F; Arnaud L; Costedoat-Chalumeau N; Zahr N; Bessis D; Francès C
J Am Acad Dermatol; 2016 Apr; 74(4):693-9.e3. PubMed ID: 26850655
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and comparison of antimalarials in cutaneous lupus erythematosus subtypes: a systematic review and meta-analysis.
Chasset F; Bouaziz JD; Costedoat-Chalumeau N; Francès C; Arnaud L
Br J Dermatol; 2017 Jul; 177(1):188-196. PubMed ID: 28112801
[TBL] [Abstract][Full Text] [Related]
6. Long-term effectiveness of antimalarial drugs in rheumatic diseases.
Aviña-Zubieta JA; Galindo-Rodriguez G; Newman S; Suarez-Almazor ME; Russell AS
Ann Rheum Dis; 1998 Oct; 57(10):582-7. PubMed ID: 9893568
[TBL] [Abstract][Full Text] [Related]
7. The quinacrine experience in a population of patients with cutaneous lupus erythematosus and dermatomyositis.
Mittal L; Werth VP
J Am Acad Dermatol; 2017 Aug; 77(2):374-377. PubMed ID: 28711090
[No Abstract] [Full Text] [Related]
8. Identification of new risk factors for hydroxychloroquine and chloroquine retinopathy in systemic lupus erythematosus patients.
Trefond L; Lhote R; Mathian A; de Chambrun MP; Pha M; Hie M; Miyara M; Papo M; Moyon Q; Taieb D; Saade S; Salem TB; Haroche J; Chasset F; Aubart FC; Zahr N; Amoura Z
Semin Arthritis Rheum; 2024 Jun; 66():152417. PubMed ID: 38394986
[TBL] [Abstract][Full Text] [Related]
9. Experience with the use of hydroxychloroquine for the treatment of lupus erythematosus.
Momose Y; Arai S; Eto H; Kishimoto M; Okada M
J Dermatol; 2013 Feb; 40(2):94-7. PubMed ID: 23216212
[TBL] [Abstract][Full Text] [Related]
10. Increased Myeloid Dendritic Cells and TNF-α Expression Predicts Poor Response to Hydroxychloroquine in Cutaneous Lupus Erythematosus.
Zeidi M; Kim HJ; Werth VP
J Invest Dermatol; 2019 Feb; 139(2):324-332. PubMed ID: 30227141
[TBL] [Abstract][Full Text] [Related]
11. Combination antimalarials in the treatment of cutaneous dermatomyositis: a retrospective study.
Ang GC; Werth VP
Arch Dermatol; 2005 Jul; 141(7):855-9. PubMed ID: 16027300
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular adverse events associated with hydroxychloroquine and chloroquine: A comprehensive pharmacovigilance analysis of pre-COVID-19 reports.
Goldman A; Bomze D; Dankner R; Hod H; Meirson T; Boursi B; Maor E
Br J Clin Pharmacol; 2021 Mar; 87(3):1432-1442. PubMed ID: 32964535
[TBL] [Abstract][Full Text] [Related]
13. Changing antimalarial agents after inefficacy or intolerance in patients with cutaneous lupus erythematosus: A multicenter observational study.
Chasset F; Arnaud L; Jachiet M; Monfort JB; Bouaziz JD; Cordoliani F; Bagot M; Barbaud A; Francès C
J Am Acad Dermatol; 2018 Jan; 78(1):107-114.e1. PubMed ID: 29061479
[TBL] [Abstract][Full Text] [Related]
14. American College of Rheumatology White Paper on Antimalarial Cardiac Toxicity.
Desmarais J; Rosenbaum JT; Costenbader KH; Ginzler EM; Fett N; Goodman S; O'Dell J; Pineau CA; Schmajuk G; Werth VP; Link MS; Kovacs R
Arthritis Rheumatol; 2021 Dec; 73(12):2151-2160. PubMed ID: 34697918
[TBL] [Abstract][Full Text] [Related]
15. The association of the two antimalarials chloroquine and quinacrine for treatment-resistant chronic and subacute cutaneous lupus erythematosus.
Feldmann R; Salomon D; Saurat JH
Dermatology; 1994; 189(4):425-7. PubMed ID: 7873836
[TBL] [Abstract][Full Text] [Related]
16. Early cutaneous eruptions after oral hydroxychloroquine in a lupus erythematosus patient: A case report and review of the published work.
Matsuda T; Ly NTM; Kambe N; Nguyen CTH; Ueda-Hayakawa I; Son Y; Okamoto H
J Dermatol; 2018 Mar; 45(3):344-348. PubMed ID: 29239026
[TBL] [Abstract][Full Text] [Related]
17. Combined mepacrine-hydroxychloroquine treatment in patients with systemic lupus erythematosus and refractory cutaneous and articular activity.
Ugarte A; Porta S; Ríos R; Martinez-Zapico A; Ortego-Centeno N; Agesta N; Ruiz-Irastorza G
Lupus; 2018 Sep; 27(10):1718-1722. PubMed ID: 29635998
[TBL] [Abstract][Full Text] [Related]
18. Optimal use of antimalarials in treating cutaneous lupus erythematosus.
Wozniacka A; McCauliffe DP
Am J Clin Dermatol; 2005; 6(1):1-11. PubMed ID: 15675885
[TBL] [Abstract][Full Text] [Related]
19. Treating lupus patients with antimalarials: analysis of safety profile in a single-center cohort.
Spinelli FR; Moscarelli E; Ceccarelli F; Miranda F; Perricone C; Truglia S; Garufi C; Massaro L; Morello F; Alessandri C; Valesini G; Conti F
Lupus; 2018 Sep; 27(10):1616-1623. PubMed ID: 29954281
[TBL] [Abstract][Full Text] [Related]
20. Discontinuation of antimalarial drugs in systemic lupus erythematosus.
Wang C; Fortin PR; Li Y; Panaritis T; Gans M; Esdaile JM
J Rheumatol; 1999 Apr; 26(4):808-15. PubMed ID: 10229401
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
